• Low Risk of Severe COVID-19 in Children With Inflammatory Bowel Diseases

Low Risk of Severe COVID-19 in Children With Inflammatory Bowel Diseases

Pediatric patients with inflammatory bowel diseases (IBD) have a low risk of severe COVID-19, even when receiving biologic and/or other immune suppressive therapies, researchers report in Clinical Gastroenterology and Hepatology. These findings support recommendations to continue maintenance IBD treatment for pediatric patients throughout the currentpandemic. SARS-CoV2 enters human cells via

Read more
  • Efficacy of 8 Weeks Treatment With Glecaprevir-Pibrentasvir in an Integrated Analysis of Patients With Chronic HCV Infection

Efficacy of 8 Weeks Treatment With Glecaprevir-Pibrentasvir in an Integrated Analysis of Patients With Chronic HCV Infection

Eight weeks treatment with glecaprevir-pibrentasvir was efficacious and well tolerated in treatment-naive patients with all hepatitis C virus (HCV) genotype infections, with or without cirrhosis, researchers report in a pooled analysis of studies in the October issue of Clinical Gastroenterology and Hepatology. In a post-hoc analysis of data from 8

Read more
  • Summer Edition of the AGA Clinician’s Companion

Summer Edition of the AGA Clinician’s Companion

The summer edition of the AGA Clinician’s Companion—the new go-to resource for busy clinicians who can’t afford to spend hours sifting through research to find clinical value—is out! This latest edition of the AGA Clinician’s Companion, published online quarterly, summarizes research findings most relevant to clinicians on the risk of

Read more

Addition of Nucleic Acid Polymers Improves Outcomes of Patients With HBV Infection

Addition of nucleic acid polymers (NAPs), which inhibit assembly and secretion of hepatitis B virus (HBV) subviral particles, to tenofovir disoproxil fumarate (TDF) and pegIFN therapy significantly increased rates of HBsAg loss and seroconversion, and functional cure, after therapy, researchers report in Gastroenterology. Chronic HBV infection causes progressive liver fibrosis,

Read more

Corticosteroids, but not TNF Antagonists, Associate With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases

Increasing age, comorbidities, and use of corticosteroids and other anti-inflammatory agents correlated with severe COVID-19 in patients with inflammatory bowel diseases (IBD), whereas treatment with tumor necrosis factor (TNF) antagonists did not, researchers report in Gastroenterology. Corticosteroids, immunomodulators (thiopurines, methotrexate), and biologic agents (TNF antagonists such as infliximab) are commonly

Read more
  • AGA Clinical Practice Update: Pause IBD Meds For Patients With COVID-19

AGA Clinical Practice Update: Pause IBD Meds For Patients With COVID-19

Patients with inflammatory bowel diseases (IBD) with COVID-19 should delay biological therapies, restarting them once symptoms are gone, says a clinical practice update from the American Gastroenterological Association (AGA). The practice update, written by David T Rubin et al, says that patients with IBD who test positive for SARS-CoV-2 but

Read more

What Treatments Are Effective for Chronic Nausea and Vomiting?

Gastric electrical stimulation reduces vomiting in patients with refractory chronic vomiting and/or nausea, researchers report in a randomized trial published in the February issue of Gastroenterology. Chronic nausea and vomiting are estimated to affect 2.2% of the adult population. For many patients, dietary changes and medical treatments do not improve symptoms,

Read more
  • AGA Clinical Practice Guideline: Management of Moderate to Severe Ulcerative Colitis

AGA Clinical Practice Guideline: Management of Moderate to Severe Ulcerative Colitis

The AGA’s latest guideline provides recommendations for the management of adult outpatients with moderate to severe ulcerative colitis (UC) and adult hospitalized patients with acute severe UC. The guideline, written by Joseph D. Feuerstein et al, discusses the use of immunomodulators, biologics, and small molecules to induce and maintain remission

Read more
  • Is There a Treatment for Patients With Celiac Disease Who Accidentally Ingest Gluten?

Is There a Treatment for Patients With Celiac Disease Who Accidentally Ingest Gluten?

The oral steroid budesonide is effective in treatment of acute symptoms from gluten exposure in patients with celiac disease, researchers report in the January issue of Clinical Gastroenterology and Hepatology. The only established treatment for celiac disease is gluten avoidance. However, even when patients follow gluten-free diets, they can accidentally ingest

Read more
  • Gastroparesis Caused by Hepatitis A Virus Infection

Gastroparesis Caused by Hepatitis A Virus Infection

Researchers describe a rare case of infectious gastroparesis caused by hepatitis A virus infection in the December issue of Gastroenterology. Amrit K. Kamboj et al report the case of a 33-year-old woman with a 10-day history of painless jaundice, decreased appetite, malaise, and pruritus. The patient did not have right

Read more